Radiotherapy (RT) remains a standard therapeutic modality for breast cancer patients.
However, intrinsic or acquired resistance limits the efficacy of RT. Here, we demonstrate that …

Background The discovery of molecular markers associated with various breast cancer
subtypes has greatly improved the treatment and outcome of breast cancer patients …

AZD7762, a novel checkpoint kinase 1 (Chk 1) inhibitor, has been proven to sensitize
various tumor cells to DNA damage. However, whether or not AZD7762 sensitizes breast …

The resistance of breast cancer to radiotherapy remains a major obstacle to successful
cancer management. Radiotherapy may result in DNA damage and activate breast cancer …

Cancer stem cells (CSCs) are subpopulations of multipotent stem cells (SCs) responsible for
the initiation, long-term clonal maintenance, growth and spreading of most human …

Trying to kill cancer cells by generating DNA damage is by no means a new idea.
Radiotherapy and genotoxic drugs are routinely used in cancer therapy. More recent …

Radiation-induced DNA damage activates the DNA damage response (DDR). DDR up-
regulation may predict radio-resistance and increase the risk of early local recurrence …

Chk1 (checkpoint kinase 1) is an evolutionarily conserved serine/threonine kinase involved
in DNA damage responses. Originally identified as a kinase regulating the G2/M transition …

Chromosomal instability not only has a negative effect on survival in triple-negative breast
cancer, but also on the well treatable subgroup of luminal A tumors. This suggests a general …

Resistance to therapy commonly develops in patients with high-grade serous ovarian
carcinoma (HGSC) and triple-negative breast cancer (TNBC), urging the search for …